As we navigate these challenging times, Certara is providing the drug development community with recent and relevant information regarding COVID-19 and facilitating professional development with on-demand resources. If you have any questions or comments, please contact us by filling out the form below.
The COVID-19 Coronavirus May Travel in Aerosols
EMA Offers Guidance on Conducting Trials During the COVID-19 Pandemic
FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic
Certara recognizes the impact COVID-19 is having on our daily personal and business lives. We continue to support our customers' discovery and drug development efforts during this time with scientific informatics, model and simulation, and regulatory software tools and platforms to inform, improve and accelerate the process of bringing therapies to patients.
We continue to commit to maintaining business continuity of our technology and support efforts. Support channels continue to be staffed globally, providing 24/5 coverage to ensure rapid and meaningful responsiveness. Our remote and dispersed development and implementation staff and infrastructure, and our proven processes, and practices allow us to continue to operate, be productive, and stay connected to our customers.
In order to facilitate a productive work environment during this time, the following resources are available:
Please do not hesitate to contact your Account Manager or [email protected] with any questions or concerns.
Supporting Drug Development for COVID-19
Are Certara staff now working remotely?
Are there any Certara offices that are open?
What are Certara’s business continuity plans?
What is Certara doing about COVID-19?
What resources are available from Certara for professional development?